KalGene Pharmaceuticals



Kalgene is developing a novel fusion protein therapeutic for slowing the progression of Alzheimer’s disease, with technology licensed from the National Research Council of Canada.

James E. Callaway
John W. Gillard
VP Product Development
Michael Grundman
Clinical Advisor
Nathan Yoganathan
President and Chief Scientific Officer

No teams yet!

No jobs yet!

No wires yet!

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.